Display options
Cite
Sun X, Chen Y, Cheung WK, et al. Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis. Integr Cancer Ther. 2021;20:15347354211038008doi: 10.1177/15347354211038008.
Sun, X., Chen, Y., Cheung, W. K., Wu, I. X., Xiao, F., & Chung, V. C. (2021). Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis. Integrative cancer therapies, 2015347354211038008. https://doi.org/10.1177/15347354211038008
Sun, Xuemei, et al. "Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis." Integrative cancer therapies vol. 20 (2021): 15347354211038008. doi: https://doi.org/10.1177/15347354211038008
Sun X, Chen Y, Cheung WK, Wu IX, Xiao F, Chung VC. Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211038008. doi: 10.1177/15347354211038008. PMID: 34369188; PMCID: PMC8358505.
Copy Download .nbib Format: NLM
Share it on

Integr Cancer Ther. 2021 Jan-Dec;20:15347354211038008. doi: 10.1177/15347354211038008.

Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis.

Integrative cancer therapies

Xuemei Sun, Yancong Chen, William Kw Cheung, Irene Xy Wu, Fang Xiao, Vincent Ch Chung

Affiliations

  1. Central South University, Changsha, Hunan, China.
  2. The Chinese University of Hong Kong, Shatin, Hong Kong, China.
  3. Hunan Provincial Key Laboratory of Clinical Epidemiology, Changsha, China.

PMID: 34369188 PMCID: PMC8358505 DOI: 10.1177/15347354211038008

Abstract

OBJECTIVE: Current guidelines have different recommendations on applying pharmacological interventions for managing cancer-related fatigue (CRF) among cancer survivors. This systematic review aims to synthesize clinical evidence on pharmacological interventions for managing CRF.

METHODS: Five databases were searched for potential randomized controlled trials (RCTs) from their inception until October 2020. RCTs assessing the effect of pharmacological treatments for CRF among cancer survivors were considered eligible. Clinical significance was determined by comparing the estimated effect with that of minimal important difference (MID). The risk of bias of each included RCT was appraised using the Cochrane risk of bias tool for randomized trials 2. Data were synthesized using random-effect pairwise meta-analyses.

RESULTS: A total of 15 RCTs (1238 participants) were included. The majority presented some concerns of bias arising from the randomization process and selection of the reported results. Meta-analysis showed that psychostimulant and wakefulness agents had statistically significant while clinically insignificant effects on the treatment of CRF (pooled weighted mean difference [WMD]: 2.8, 95% confidence interval [CI]: 0.2-5.4,

CONCLUSIONS: Existing evidence showed promising effects of 3 natural products in reducing CRF among cancer survivors. The results from this study need to be further confirmed with well-designed and adequately powered RCTs that use validated instruments for the measurement of CRF.

Keywords: cancer survivors; drug therapy; fatigue; meta-analysis; systematic review

References

  1. Neuro Oncol. 2015 Oct;17(10):1393-401 - PubMed
  2. J Pain Symptom Manage. 2020 May;59(5):966-973 - PubMed
  3. Integr Cancer Ther. 2010 Dec;9(4):331-8 - PubMed
  4. Eur J Cancer Care (Engl). 2018 Jan;27(1): - PubMed
  5. BMC Med Res Methodol. 2016 May 26;16:62 - PubMed
  6. Med Clin North Am. 2017 Nov;101(6):1085-1097 - PubMed
  7. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  8. Clin J Oncol Nurs. 2014;18 Suppl:38-58 - PubMed
  9. Curr Treat Options Oncol. 2020 Feb 5;21(2):17 - PubMed
  10. JAMA Oncol. 2017 Jul 1;3(7):961-968 - PubMed
  11. BMJ. 2005 May 21;330(7501):1179 - PubMed
  12. Curr Oncol. 2018 Apr;25(2):e152-e167 - PubMed
  13. Health Qual Life Outcomes. 2018 Jun 01;16(1):112 - PubMed
  14. J Clin Epidemiol. 2000 Feb;53(2):207-16 - PubMed
  15. BJU Int. 2015 Nov;116(5):744-52 - PubMed
  16. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Oct;30(10):1036-40 - PubMed
  17. J Cancer Res Clin Oncol. 2020 Oct;146(10):2479-2487 - PubMed
  18. Support Care Cancer. 2014 Nov;22(11):3007-15 - PubMed
  19. J Cancer Surviv. 2016 Feb;10(1):176-84 - PubMed
  20. Gulf J Oncolog. 2019 May;1(30):43-51 - PubMed
  21. Ann Oncol. 2009 Jan;20(1):17-25 - PubMed
  22. BMC Cancer. 2020 Feb 27;20(1):158 - PubMed
  23. Cochrane Database Syst Rev. 2010 Jul 07;(7):CD006704 - PubMed
  24. BMJ. 2019 Aug 28;366:l4898 - PubMed
  25. BMJ. 2012 Jan 30;344:e70 - PubMed
  26. J Cancer Surviv. 2016 Feb;10(1):51-61 - PubMed
  27. Anticancer Res. 2006 Mar-Apr;26(2B):1519-29 - PubMed
  28. Br J Cancer. 2014 Jul 8;111(1):33-45 - PubMed
  29. Support Care Cancer. 2012 Aug;20(8):1745-53 - PubMed
  30. Med Care. 2003 May;41(5):582-92 - PubMed
  31. Neuro Oncol. 2013 Oct;15(10):1420-8 - PubMed
  32. Support Care Cancer. 2015 Jun;23(6):1503-12 - PubMed
  33. J Clin Oncol. 2014 Jun 10;32(17):1840-50 - PubMed
  34. Eur J Cancer Care (Engl). 2016 Nov;25(6):970-979 - PubMed
  35. J Med Libr Assoc. 2006 Jan;94(1):41-7 - PubMed
  36. Curr Oncol. 2013 Jun;20(3):e233-46 - PubMed
  37. Ann Surg Oncol. 2016 Jul;23(7):2137-45 - PubMed
  38. Climacteric. 2011 Feb;14(1):164-70 - PubMed
  39. Ann Intern Med. 2010 Jun 1;152(11):726-32 - PubMed
  40. Neuropsychopharmacology. 2002 May;26(5):643-52 - PubMed
  41. Thyroid. 2015 Feb;25(2):198-210 - PubMed
  42. Neurooncol Adv. 2019 Nov 10;1(1):vdz043 - PubMed
  43. J Pain Symptom Manage. 2009 Nov;38(5):650-62 - PubMed
  44. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed

MeSH terms

Publication Types